SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for STRATA Skin Sciences, Inc. (SSKN) (CIK 0001051514) (SSKN) — Jan 19, 2022

STRATA Skin Sciences, Inc. (SSKN) (CIK 0001051514)
Date: Jan. 19, 2022 · CIK: 0001051514 · Accession: 0000000000-22-000679

AI Filing Summary & Sentiment

File numbers found in text: 333-262150

Date
January 19, 2022
Author
Not clearly detected
Form
UPLOAD
Company
STRATA Skin Sciences, Inc. (SSKN) (CIK 0001051514)

Letter

United States securities and exchange commission logo January 19, 2022 Robert Moccia Chief Executive Officer STRATA Skin Sciences, Inc. 5 Walnut Grove Drive, Suite 140 Horsham, PA 19044 Re:STRATA Skin Sciences, Inc. Registration Statement on Form S-3 Filed January 13, 2022 File No. 333-262150 Dear Mr. Moccia: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sunjeet Gill

Show Raw Text
United States securities and exchange commission logo
January 19, 2022
Robert Moccia
Chief Executive Officer
STRATA Skin Sciences, Inc.
5 Walnut Grove Drive, Suite 140
Horsham, PA 19044
Re:STRATA Skin Sciences, Inc.
Registration Statement on Form S-3
Filed January 13, 2022
File No. 333-262150
Dear Mr. Moccia:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Sunjeet Gill